Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-cash Items (2018 - 2024)

Zevra Therapeutics (ZVRA) has disclosed Non-cash Items for 8 consecutive years, with $2.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-cash Items fell 78.36% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Dec 2024, down 78.36%, and an annual FY2024 reading of $2.4 million, changed 0.37% over the prior year.
  • Non-cash Items was $2.4 million for Q4 2024 at Zevra Therapeutics, down from $11.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $11.8 million in Q4 2022 and bottomed at $254207.0 in Q4 2021.
  • Average Non-cash Items over 5 years is $5.2 million, with a median of $2.4 million recorded in 2024.
  • The sharpest move saw Non-cash Items surged 4549.36% in 2022, then plummeted 78.36% in 2024.
  • Year by year, Non-cash Items stood at $543021.0 in 2020, then tumbled by 53.19% to $254207.0 in 2021, then soared by 4549.36% to $11.8 million in 2022, then fell by 6.18% to $11.1 million in 2023, then tumbled by 78.36% to $2.4 million in 2024.
  • Business Quant data shows Non-cash Items for ZVRA at $2.4 million in Q4 2024, $11.1 million in Q4 2023, and $11.8 million in Q4 2022.